Dan Costin

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

Soumaya El Rouby, Alexander S. Thomas, Dan Costin et al. · Blood · 1993 · 366 citations · Full text

Medicine, Genetics, Oncology +12

Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors

Alexa B. Schrock, Viola W. Zhu, Wen-Son Hsieh et al. · Journal of Thoracic Oncology · 2018 · 136 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs

R Silber, Barbara Degar, Dan Costin et al. · Blood · 1994 · 72 citations · Full text

Medicine, Oncology, Pharmacology +12

p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression

Soumaya El Rouby, Alexander S. Thomas, Dan Costin et al. · Blood · 1993 · 30 citations · Full text

Medicine, Genetics, Oncology +12

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results.

Rahul Aggarwal, Jingsong Zhang, Xinhua Zhu et al. · Journal of Clinical Oncology · 2023 · 14 citations

Medicine, Oncology, Pharmacology +17